Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Lipocine News

    4,62 $ -2,33% -0,11 $
    In : 4,3359 € | 30.04.24 21:57:06 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3EBZD
    ISIN: US53630X2036
    US-Symbol: LPCN
    Typ: Aktie

    Lipocine News

    11.04.24 - PR Newswire
    Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
    Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire
    28.03.24 - PR Newswire
    Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
    Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire
    25.03.24 - PR Newswire
    Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
    Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire
    07.03.24 - PR Newswire
    Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
    Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 PR Newswire
    06.03.24 - PR Newswire
    Lipocine to Present at 36th Annual Roth Conference
    Lipocine to Present at 36th Annual Roth Conference PR Newswire
    06.02.24 - PR Newswire
    Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
    Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 PR Newswire
    02.02.24 - PR Newswire
    Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
    Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals PR Newswire
    18.01.24 - PR Newswire
    Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
    Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada PR Newswire
    19.12.23 - PR Newswire
    Lipocine to Present at Biotech Showcase 2024
    Lipocine to Present at Biotech Showcase 2024 PR Newswire
    13.11.23 - PR Newswire
    Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
    Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 PR Newswire
    08.11.23 - PR Newswire
    Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
    Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 PR Newswire
    01.11.23 - PR Newswire
    Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
    Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 PR Newswire
    26.10.23 - PR Newswire
    Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
    Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression PR Newswire
    23.10.23 - PR Newswire
    Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
    Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference PR Newswire
    19.09.23 - PR Newswire
    Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
    Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
    10.08.23 - PR Newswire
    Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
    Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 PR Newswire
    27.07.23 - PR Newswire
    LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
    LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire
    14.06.23 - PR Newswire
    Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
    Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference PR Newswire
    07.06.23 - PR Newswire
    Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
    Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 PR Newswire
    16.05.23 - PR Newswire
    Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression
    Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression PR Newswire

    Newssuche

    Videos

    newspaper
    30.04.24 -9,41%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »